We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.06 | 1.08% | 5.60 | 4.50 | 5.50 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 5.58 | 5.00 | 5.00 | 696,654 | 16:35:04 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -5.56 | 264.06M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 06/11/2024 | 11:22 | ALNC |  Allergy Therapeutics annual loss narrows thanks to reduced expenses |
| 06/11/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Audited Preliminary Results 2024 |
| 21/10/2024 | 09:56 | ALNC | Allergy Therapeutics enrols candidates for grass pollen allergy trial |
| 21/10/2024 | 06:00 | UK RNS | Allergy Therapeutics PLC Commencement of Phase III Paediatric Trial |
| 16/10/2024 | 09:58 | ALNC | Allergy Therapeutics shares surge as enters into secured loan facility |
| 16/10/2024 | 06:00 | UK RNS | Allergy Therapeutics PLC Update on funding |
| 01/10/2024 | 06:00 | UK RNS | Allergy Therapeutics PLC Update on funding and preliminary results |
| 17/9/2024 | 06:00 | UK RNS | Allergy Therapeutics PLC Progression of patient cohorts in PROTECT Trial |
| 27/8/2024 | 08:57 | ALNC | Allergy Therapeutics secures cash to see it through September |
| 27/8/2024 | 06:00 | UK RNS | Allergy Therapeutics PLC Update on funding |
1 Year Allergy Therapeutics Chart |
Intraday Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
